New medicines faster

Precision Neuropharmacology

New medicines.
Faster.

Allaysis LLC is a virtual pharmaceutical company advancing evidence-based therapies for complex neurological conditions, beginning with intravenous baclofen for severe spasticity management.

IND
Track
NDA
Target
IV
Formulation
UMN
Partnership

Our Mission

Science with purpose

Allaysis LLC was founded on the belief that rigorous pharmaceutical science and patient-centered thinking are inseparable. We operate as a virtual company, lean by design and deep in expertise, partnering with world-class academic and clinical institutions to move promising therapies from concept to clinic.

Our approach is built on orthogonal evidence: combining pharmacokinetic modeling, formulation science, and clinical need assessment before committing to a development path. We don’t follow trends. We follow data.

Our collaboration with the University of Minnesota positions us at the leading edge of CNS pharmacology, with a shared commitment to translating bench science into treatments that make a measurable difference in patients’ lives.

01 — Core Principle
Evidence-Led Development
Every decision is grounded in pharmacological rigor. We pursue programs only where the science is unambiguous and the unmet need is real.
02 — Our Model
Virtual, Not Virtual-ized
Our lean structure enables faster decisions and deeper engagement with best-in-class partners, not outsourced thinking.
03 — Collaboration
Academic Partnership
Deep institutional collaboration ensures independent scientific scrutiny and access to leading clinical networks.

Programs

Our Pipeline

Focused development programs targeting conditions with significant unmet medical need and compelling pharmacological rationale.

IV Baclofen
ALL-1401
Lead Program
Indication Severe spasticity; intrathecal pump transitions
Modality Small molecule · IV formulation
Route Intravenous
FDA Designation ★ Orphan Drug Designation
Development Stage — 505(b)(2) Pathway
Literature Review Pre-IND / IND CMC & Bridging BA/BE Study ✓ NDA Filing
🏫
University of Minnesota Collaboration — ALL-1401 is being co-developed with leading CNS pharmacology and clinical neurology experts at the University of Minnesota.

Get in Touch

Partner with Allaysis LLC

We welcome conversations with academic collaborators, clinical investigators, potential commercial partners, and investors who share our commitment to advancing neuropharmacology.

General Inquiriesinfo@allaysis.com
Business Developmentbd@allaysis.com
Scientific Collaborationscience@allaysis.com